BridgeBio Pharma
BBIO
181 hedge funds and large institutions have $1.44B invested in BridgeBio Pharma in 2022 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 72 increasing their positions, 48 reducing their positions, and 14 closing their positions.
121% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 14
50% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 48
41% more call options, than puts
Call options by funds: $4.5M | Put options by funds: $3.19M
13% more capital invested
Capital invested by funds: $1.28B → $1.44B (+$168M)
10% more funds holding
Funds holding: 164 → 181 (+17)
2.87% more ownership
Funds ownership: 95.09% → 97.96% (+2.9%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$11.8M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$10.9M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$10.1M |
| 4 |
Renaissance Technologies
New York
|
+$9.91M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
+$7.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$31.3M |
| 2 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
-$4.16M |
| 3 |
Morgan Stanley
New York
|
-$3.23M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$3.18M |
| 5 |
Charles Schwab
San Francisco,
California
|
-$3.1M |
BBIO Hedge Fund Activity: Q3 2022 in Review
181 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q3 2022, worth a combined $1.44B — up 13% from $1.28B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new BBIO positions and 14 closed out — a net gain of 17 holders — while 72 added to existing stakes and 48 trimmed.
The largest buyer was Jacobs Levy Equity Management, adding an estimated $11.8M. The largest seller was State Street, cutting an estimated $31.3M.
- 181 institutional investors held BridgeBio Pharma (BBIO) as of Q3 2022, up from 164 in Q2 2022.
- Funds reported $1.44B of BridgeBio Pharma stock for Q3 2022, up 13% quarter-over-quarter.
- 31 funds opened new BridgeBio Pharma positions in Q3 2022 and 14 closed out, a net change of +17 holders.
- The largest BridgeBio Pharma buyer in Q3 2022 was Jacobs Levy Equity Management, an estimated $11.8M added.
- The largest BridgeBio Pharma seller in Q3 2022 was State Street, an estimated $31.3M sold.
Based on aggregated 13F filings for Q3 2022.